Literature DB >> 16204253

Peroxisomal proliferation protects from beta-amyloid neurodegeneration.

Manuel J Santos1, Rodrigo A Quintanilla, Andrés Toro, Rodrigo Grandy, Margarita C Dinamarca, Juan A Godoy, Nibaldo C Inestrosa.   

Abstract

Alzheimer disease is a neurodegenerative process that leads to severe cognitive impairment as a consequence of selective death of neuronal populations. The molecular pathogenesis of Alzheimer disease involves the participation of the beta-amyloid peptide (Abeta) and oxidative stress. We report here that peroxisomal proliferation attenuated Abeta-dependent toxicity in hippocampal neurons. Pretreatment with Wy-14.463 (Wy), a peroxisome proliferator, prevent the neuronal cell death and neuritic network loss induced by the Abeta peptide. Moreover, the hippocampal neurons treated with this compound, showed an increase in the number of peroxisomes, with a concomitant increase in catalase activity. Additionally, we evaluate the Wy protective effect on beta-catenin levels, production of intracellular reactive oxygen species, cytoplasmic calcium uptake, and mitochondrial potential in hippocampal neurons exposed to H(2) O(2) and Abeta peptide. Results show that the peroxisomal proliferation prevents beta-catenin degradation, reactive oxygen species production, cytoplasmic calcium increase, and changes in mitochondrial viability. Our data suggest, for the first time, a direct link between peroxisomal proliferation and neuroprotection from Abeta-induced degenerative changes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16204253     DOI: 10.1074/jbc.M505160200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  67 in total

1.  Transcriptional coactivator PGC-1alpha promotes peroxisomal remodeling and biogenesis.

Authors:  Alessia Bagattin; Lynne Hugendubler; Elisabetta Mueller
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-08       Impact factor: 11.205

2.  Pro12Ala polymorphism in PPAR-gamma2 and dementia in Chinese nonagenarians/centenarians.

Authors:  Ji-Rong Yue; Bi-Rong Dong; Chang-Quan Huang; Zhen-Chan Lu; Hong-Mei Wu; Yan-Ling Zhang
Journal:  Age (Dordr)       Date:  2010-01-27

Review 3.  Therapeutic potential of nuclear receptor agonists in Alzheimer's disease.

Authors:  Miguel Moutinho; Gary E Landreth
Journal:  J Lipid Res       Date:  2017-03-06       Impact factor: 5.922

Review 4.  Involvement of PPAR nuclear receptors in tissue injury and wound repair.

Authors:  Liliane Michalik; Walter Wahli
Journal:  J Clin Invest       Date:  2006-03       Impact factor: 14.808

Review 5.  Peroxisome proliferator-activated receptors ligands and ischemia-reperfusion injury.

Authors:  Rosanna Di Paola; Salvatore Cuzzocrea
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-03-13       Impact factor: 3.000

Review 6.  Organelle dynamics and dysfunction: A closer link between peroxisomes and mitochondria.

Authors:  F Camões; N A Bonekamp; H K Delille; M Schrader
Journal:  J Inherit Metab Dis       Date:  2008-12-12       Impact factor: 4.982

Review 7.  Alzheimer's disease as homeostatic responses to age-related myelin breakdown.

Authors:  George Bartzokis
Journal:  Neurobiol Aging       Date:  2009-09-22       Impact factor: 4.673

Review 8.  Peroxisome proliferator-activated receptors and Alzheimer's disease: hitting the blood-brain barrier.

Authors:  Juan M Zolezzi; Nibaldo C Inestrosa
Journal:  Mol Neurobiol       Date:  2013-03-14       Impact factor: 5.590

9.  PPARalpha ligands inhibit radiation-induced microglial inflammatory responses by negatively regulating NF-kappaB and AP-1 pathways.

Authors:  Sriram Ramanan; Mitra Kooshki; Weiling Zhao; Fang-Chi Hsu; Mike E Robbins
Journal:  Free Radic Biol Med       Date:  2008-09-17       Impact factor: 7.376

10.  Modulation of peroxisome proliferator-activated receptor-alpha activity by N-acetyl cysteine attenuates inhibition of oligodendrocyte development in lipopolysaccharide stimulated mixed glial cultures.

Authors:  Manjeet K Paintlia; Ajaib S Paintlia; Mushfiquddin Khan; Inderjit Singh; Avtar K Singh
Journal:  J Neurochem       Date:  2008-01-12       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.